[ET Net News Agency, 8 April 2024] Citi lowered the target price for Alphamab (09966)
to HKD3.6 from HKD5.8 and maintained the "sell/high risk" rating.
The research house said it cuts FY24/25E revenue estimates by 16%/18% to reflect the
latest sales trend. (RC)